Inhibrx Biosciences, Inc. (INBX) - Total Liabilities
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has total liabilities worth $140.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Inhibrx Biosciences, Inc. (INBX) cash conversion ratio to assess how effectively this company generates cash.
Inhibrx Biosciences, Inc. - Total Liabilities Trend (2016–2024)
This chart illustrates how Inhibrx Biosciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of Inhibrx Biosciences, Inc. for net asset value and shareholders' equity analysis.
Inhibrx Biosciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pet Valu Holdings Ltd
TO:PET
|
Canada | CA$931.18 Million |
|
Jiangsu Maixinlin Aviation Science & Technology Corp. A
SHG:688685
|
China | CN¥2.11 Billion |
|
Shanghai Research Institute of Building Sciences Group Co. Ltd A
SHG:603153
|
China | CN¥1.79 Billion |
|
Motus Holdings Ltd
JSE:MTH
|
South Africa | ZAC41.97 Billion |
|
Dongguan Mentech Optical & Magnetic Co Ltd
SHE:002902
|
China | CN¥1.63 Billion |
|
Hagerty Inc
NYSE:HGTY
|
USA | $1.32 Billion |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
China | CN¥2.78 Billion |
|
Bittium Oyj
HE:BITTI
|
Finland | €49.70 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Inhibrx Biosciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Inhibrx Biosciences, Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inhibrx Biosciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inhibrx Biosciences, Inc. (2016–2024)
The table below shows the annual total liabilities of Inhibrx Biosciences, Inc. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $47.18 Million | -82.15% |
| 2023-12-31 | $264.39 Million | +13.56% |
| 2022-12-31 | $232.82 Million | +137.41% |
| 2021-12-31 | $98.07 Million | +43.65% |
| 2020-12-31 | $68.27 Million | -43.14% |
| 2019-12-31 | $120.06 Million | +77.53% |
| 2018-12-31 | $67.63 Million | +70.49% |
| 2017-12-31 | $39.67 Million | +98.00% |
| 2016-12-31 | $20.03 Million | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candid… Read more